ATEZOLIZUMAB
atezolizumab 1.875 g/15 mL injection, 15 mL vial
ATEZOLIZUMAB (14249Y)
14249Y
Manner of administration:Injection
Restriction 10297
Indication: Locally advanced or metastatic non-small cell lung cancer
Treatment phase: Continuing treatment - 3 weekly treatment regimen
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 7 | DPMQ: $6,747.37 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tecentriq SC | |||||